AB071. Perioperative liquid biopsy can help risk stratify breast cancer patients
Session 5: Sylvester O'Halloran Prize Session

AB071. Perioperative liquid biopsy can help risk stratify breast cancer patients

Fara Hassan1,2, Donal Peter O’Leary1, Jiang Huai Wang1,2, Paul Redmond1,2, Michael Ita1,2, Mark Corrigan1,2

1Department of Academic Surgery, Cork University Hospital, Wilton, Cork, Ireland;2Department of Academic Surgery, University College Cork, Cork, Ireland

Background: Analysis of liquid biopsy as cell free DNA (cfDNA) and circulating tumour DNA (ctDNA) has emerged as a promising non-invasive technique to detect fragmented tumour DNA in circulation. Liquid biopsy has shown excellent diagnostic and prognostic potential in breast cancer. Thus, we wished to evaluate the peri-operative dynamics of cfDNA and ctDNA to establish their prognostic ability in breast cancer.

Methods: Breast cancer patients undergoing curative surgery were included. Blood samples were taken pre-operatively and 30 days post-operatively. cfDNA was extracted and measured using spectrophotometry. DNA integrity (long/short DNA fragments) was measured using ALU 247 and ALU115 primers. PIK3CA mutation (exon 9 and 20) detection in ctDNA was performed using high resolution melting (HRM) real-time PCR combined with parallel internal controls.

Results: A total of 29 patients were studied, 14 disease free group (DF) and 15 disease recurrence group (DR). The median patient follow-up was 36 months. cfDNA concentrations and DNA integrity were significantly higher in the DR group compared to the DF group pre-operatively (concentrations; P=0.0004, integrity; P=0.039) and at the 30 day post-operative time period (concentrations; P=0.04, integrity; P=0.03). Higher post-operative cfDNA concentrations was predictive of poor disease free survival (HR: 3.8, P=0.02). Post-operative detection of PIK3CA mutation in ctDNA was associated with a higher risk of recurrence (odds ratio: 1.86, 95% CI: 0.36–12.9).

Conclusions: Perioperative cfDNA and ctDNA evaluation can provide valuable prognostic information and has the potential to stratify risk of recurrence even further and allow a more personalised follow up plan in breast cancer patients.

Keywords: Liquid biopsy; cell free DNA (cfDNA); circulating tumour DNA (ctDNA); breast cancer; peri-operative period; recurrence

doi: 10.21037/map.2020.AB071
Cite this abstract as: Hassan F, O’Leary DP, Wang JH, Redmond P, Ita M, Corrigan M. Perioperative liquid biopsy can help risk stratify breast cancer patients. Mesentery Peritoneum 2020;4:AB071.

Download Citation